A phase I and pharmacologic study of idarubicine, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
収録刊行物
-
- Leuk Res.
-
Leuk Res. 29 263-271, 2005